Newest ulcer drug from AstraZeneca has a slight edge

Article Abstract:

AstraZeneca's new ulcer treatment drug, called Nexium, has proven itself to be slightly more effective than Losec, the preparation AstraZeneca produced for ulcer treatment previously. AstraZeneca goes through financial turmoil, and it has high hopes for the new medication.

Product introduction, Care and treatment, Statistical Data Included, Brief Article, Ulcers, AstraZeneca PLC, AZN

---

Shares of Glaxo and SmithKline Slip Despite Upbeat Corporate News

Article Abstract:

Although both United Kingdom-based pharmaceuticals giants SmithKline Beecham PLC and Glaxo Wellcome PLC reported improved earnings, both companies' shares prices dropped.

Market information - general, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Financial analysis, Securities prices, Finance, Glaxo Wellcome PLC, SmithKline Beecham PLC

---

Zeneca shareholders to decide Astra deal; few bars remain to creating No. 3 drug firm

Article Abstract:

Shareholders of United Kingdom's pharmaceuticals company Zeneca Group PLC meet to approve merger with Sweden's pharmaceuticals giant Astra AB. If approved by both companies' shareholders, the $35 billion merger will produce the third largest pharmaceuticals company in the world.

Comment:

Shareholders of Sweden's Astra AB and U.K.'s Zeneca Group PLC consider merger of both companies.

Asset sales & divestitures, Sweden, Mergers, acquisitions and divestments, Zeneca Group PLC, Astral AB

Similar abstracts:

• Abstracts: Vivendi aims to change statutes of company to curb voting rights. Vivendi plans to list shares in New York
• Abstracts: AstraZeneca shares decline 7.5% despite solid results, rosy outlook. AstraZeneca shares fall 2.5% after cutting sales outlook
• Abstracts: Lazard's shares drop in debut as private control ends at firm. Slow-going Eurobond session absorbs two debut offerings
• Abstracts: Pearson to acquire NCS for $2.5 billion; Move will create world's top education firm. Pearson buys Dorling Kindersley
• Abstracts: Fenosa is given the green light to take over rival Cantabrico. Shareholders reject Fenosa's offer to buy Cantabrico

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.